Also, in vivo studies on mice indicate that Sema3E treatment reduces allergic asthma by reducing eosinophilic inflammation, serum IgE level, and Th2 cytokine response and is proposed as a novel treatment option for allergic asthma (26). This evidence concerns the gene IGHE and allergic asthma.